Fulcrum Therapeutics Inc (FULC) 4.92 +0.02 (+0.41%)
4.92 +0.02 (+0.41%)
US3596161097 - Common Stock - After market: 4.92 0 (0%)
Buy % Consensus
Analysts have set a mean price target of 28.94. This target is 488.26% above the current price.
FULC was analyzed by 14 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about FULC.
In the previous month the buy percentage consensus was at a similar level.
FULC was analyzed by 14 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target
Up and Down Grades
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-06-13 | HC Wainwright & Co. | Maintains | Buy |
| 2022-05-17 | Morgan Stanley | Maintains | Overweight |
| 2022-04-12 | Morgan Stanley | Maintains | Overweight |
| 2022-03-08 | Oppenheimer | Initiate | Outperform |
| 2021-08-17 | HC Wainwright & Co. | Maintains | Buy |
| 2021-08-13 | SVB Leerink | Maintains | Outperform |
| 2021-08-11 | Credit Suisse | Maintains | Outperform |
| 2021-08-11 | Morgan Stanley | Upgrade | Equal-Weight -> Overweight |
| 2021-03-22 | Credit Suisse | Initiate | Outperform |
| 2021-03-08 | Morgan Stanley | Maintains | Equal-Weight |
| 2021-03-02 | Stifel | Initiate | Buy |
Analyst Ratings Stock Screener Links
Best Analyst Rating Competitors Stock Screener
Find the competitors with the best analyst ratings on the USA